可溶性环氧化物水解酶基因多态性与冠心病的相关性被引量：1

Correlation between EPHX2 gene polymorphisms and coronary heart disease in Chinese population

下载PDF

导出

摘要目的:研究中国浙江籍汉族人群中可溶性环氧化物水解酶(EPHX2)基因rs2271001位点单核苷酸多态性(single nucleotide polymorphism,SNP)与冠心病的相关性。方法:176例冠心病患者(至少1支冠状动脉血管内径狭窄≥50%)为冠心病组,选取同期179例冠脉造影正常者作为对照组。采用PCR和基因测序方法,检测rs2271001位点的SNP。结果:在rs2271001位点上检测到3种基因型,其基因型分布符合HardyWeinberg平衡定律。冠心病组EPHX2基因rs2271001位点的AG、GG、AA基因型及G、A等位基因分布频率均高于对照组(均P<0.05)。结论:EPHX2基因rs2271001位点A/G多态性与冠心病发病存在相关性,G等位基因可能是中国浙江籍汉族人群冠心病患者患病的危险等位基因。 Objective：To study the correlation between EPHX2 gene polymorphisms and CHD in Chinese population.Methods：One hundred and seventy-six patients were underwent selected coronary angiography and patients having more than one major coronary vessel with at least 50％ stenosis were defined as CHD.The control group consisted of 179 healthy subjects.rs2271001 polymorphisms were detected by polymerase chain reaction （PCR） and gene sequence.Results：Three kinds of genotypes at the rs2271001 were detected,and no deviation was observed from Hardy-Weinberg equilibrium.The frequency of allele G,A and genotype AG,GG and AA were increased in CHD group when compared with control group （P＜0.05）.Conclusion：These results suggest that rs2271001 A/G polymorphism be associated with CHD in Chinese population,the G allele may be a risk allele of CHD in Chinese Han nationality in Zhejiang province.

作者黄一伟张怀勤林斌王军毛义建

机构地区温州医科大学定理临床学院温州市中心医院心血管内科温州医科大学附属第一医院心血管内科温州市中心医院中心实验室

出处《温州医学院学报》 CAS 2014年第8期578-580,584,共4页 Journal of Wenzhou Medical College

关键词冠心病多态性单核苷酸可溶性环氧化物水解酶相关性 coronary heart disease polymorphism single-nucleotide EPHX2 relevance

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献13

1Widlansky ME,Gokce N,Keaney JF,et al.The clinical implications of endothelial dysfunction[J].J Am Coil Cardiol,2003,42(7):1149-1160.
2Abdu E,Bruun DA,Yang J,et al.Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures[J].J Neurochem,2011,117(4):632-642.
3Sandberg M,Hassett C,Adman ET,et al.Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms[J].J Biol Chem,2000,275(37):28873-28881.
4Lee CR,North KE,Bray MS,et al.Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease:The Atherosclerosis Risk in Communities (ARIC) study[J].Hum Mol Genet,2006,15(10):1640-1649.
5Fomage M,Boerwinkle E,Doris PA,et al.Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects:The Coronary Artery Risk Development in Young Adults (CARDIA) study[J].Circulation,2004,109(3):335-339.
6Przybyla-Zawislak BD,Srivastava PK,Vazquez-Matias J,et al.Polymorphisms in human soluble epoxide hydrolase[J].Mol Pharmacol,2003,64(2):482-490.
7Ai D,Fu Y,Guo D,et al.Angiotensin Ⅱ up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo[J].Proc Natl Acad Sci USA,2007,104(21):9018-9023.
8蒋云,许丹焰,赵水平.可溶性环氧化物水解酶抑制剂在心血管领域中的研究进展[J].中国动脉硬化杂志,2010,18(2):165-168. 被引量：4
9Nithipatikom K,Gross GJ.Review anticle:epoxyeicosatrienoic acids:novel mediators of cardioprotection[J].Cardiovasc Pharmacol Ther,2010,15 (2):112-119.
10Newman JW,Morisseau C,Hammock BD.Epoxide hydrolases:their roles and interactions with lipid metabolism[J].Prog Lipid Res,2005,44(1):1-51.

二级参考文献43

1Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienolc acids (EETs) : metabolism and biochemical function [ J ]. Prog Lipid Res, 2004, 43 ( 1 ) : 55-90.
2Mustafa S, Shanna V, McNeill JH. Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link[J]? Exp Clin Cardiol, 2009, 14 (2): e41-50.
3Node K, Ruan XL, Dai J, et al. Activation of Galphas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids [J]. J Biol Chem, 2001, 276 (19): 15 983-989.
4Iliff J J, Alkayed NJ. Soluble epoxide hydrolase inhibition : targeting multiple mechanisms of ischemic brain injury with a single agent [ J ]. Future Neurol, 2009, 4 (2) : 179-199.
5Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function [J]. Am J Physiol Cell Physiol, 2007, 292 (3) : C996-1 012.
6Chiamvimonvat N, Ho CM, Tsai H J, et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension [ J ]. J Cardiovasc Pharmacol, 2007, 50 (3) : 225-237.
7Morisseau C, Hammock BD. Gerry. Brooks and epoxide hydrolases: four decades to a pharmaceutical [ J ]. Pest Manag Sci, 2008, 64 (6) : 594- 609.
8Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism [ J]. Prog Lipid Res, 2005, 44 (1): 1-51.
9Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, et al. Polymorphisms in human soluble epoxide hydrolase [ J ]. Mol Pharmacol, 2003, 64 (2) : 482-490.
10Latsson C, White I, Johansson C, et al. Localization of the human soluble epoxide hydrolase gene ( EPHX2 ) to chromosomal region 8p21-p12 [J]. Hum Genet, 1995, 95 (3): 356-358.